Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients - Poll - MDSpire

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • By

  • Yasuo Imanishi

  • Takumi Imai

  • Hisako Fujii

  • Rei Aida

  • Yuki Nagata

  • Tetsuo Shoji

  • Shinichiro Kashiwagi

  • Tsutomu Takashima

  • Masanori Emoto

  • January 15, 2025

  • 0 min

Share

Original Source(s)

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • by Yasuo Imanishi, Takumi Imai, Hisako Fujii, Rei Aida, Yuki Nagata, Tetsuo Shoji, Shinichiro Kashiwagi, Tsutomu Takashima, Masanori Emoto

  • January 15, 2025

Related Content

Second contralateral hip fractures reduce survival, mobility and daily activity : a matched pair analysis

Inavolisib-induced fulminant-like diabetes and hyperosmolar hyperglycemic state: a case report

Pathological fracture following minimal trauma as the initial presentation of parathyroid carcinoma–associated hyperparathyroidism in a young man: a case report